Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study

by Branch-Elliman, W., Do, N.V, Fillmore, N.R, La, J., Li, L.L, Monach, P.A, Strymish, J.M, Zheng, C.
Published 2022

Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: Two cases in patients on TNF inhibitor monotherapy

by Cook, C.E, Diiorio, M., Kowalski, E., Patel, N.J, Qian, G., Ritter, S.Y, Sparks, J.A, Vanni, K.M.M, Wallace, Z.S
Published 2022

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)

by Akriv, A., Amichay, D., Avni, Y.S, Balicer, R.D, Barda, N., Berdinstein, R., Chayat, C.B, Chazan, B., Chowers, M., Dagan, N., Dor, A.B, Greenberg, D., Harlev, E.B, Hirsch, A., Katz, M.A, Kepten, E., Levy, J., Mandelboim, M., Peretz, A., Rainy, N., Rashid, G., Reznik, D., Sagas, D., Taraday, E.K, Tshori, S., Weinberger, R., Yacobi, M., Zuckerman, N., Zvi, H.B
Published 2022

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

by Anderson, T.C, Dooling, K.L, Guo, A., Kotton, C.N, Lee, G.M, Leidner, A.J, Masters, N.B, Shepersky, L.
Published 2022

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults

by Curran, D., Ganz, M.L, Jung, H., McGirr, A., Stokes, M., Van Oorschot, D., Varghese, L., Widenmaier, R.
Published 2019

Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unschedul...

by Au, I.C.H, Chan, E.W.Y, Chui, C.S.L, Cowling, B.J, Lai, F.T.T, Lau, K.T.K, Lee, C.K, Li, X., Wan, E.Y.F, Wong, C.K.H, Wong, I.C.K, Xiong, X.
Published 2022